Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 50,407 shares, an increase of 327.4% from the May 14th total of 11,793 shares. Based on an average daily trading volume, of 359,949 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Chugai Pharmaceutical Trading Down 0.8%

Shares of OTCMKTS:CHGCY opened at $23.33 on Friday. The company has a market capitalization of $76.79 billion, a price-to-earnings ratio of 25.92 and a beta of 0.58. Chugai Pharmaceutical has a 12 month low of $19.50 and a 12 month high of $34.84. The firm’s 50-day moving average is $25.61 and its 200 day moving average is $27.18.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. As a group, equities analysts forecast that Chugai Pharmaceutical will post 0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

CHGCY has been the topic of a number of research reports. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Chugai Pharmaceutical has a consensus rating of “Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.